Eli Lilly's next-generation weight-loss drug, retatrutide, has achieved a breakthrough in a pivotal Phase 3 clinical trial. Patients in the highest dose group experienced an average weight reduction of 28.3% over 80 weeks, with approximately 45% of participants achieving weight loss of 30% or more—a level previously associated primarily with bariatric surgery. This outcome not only met Wall Street expectations but also further solidifies Eli Lilly's leading position in the highly competitive anti-obesity drug market.
The Phase 3 trial enrolled approximately 2,500 patients with obesity or overweight and at least one related comorbidity, testing three dose groups from 4 mg to 12 mg. All doses met the primary endpoint of clinically meaningful weight loss. The highest dose group saw an average weight loss of 70.3 pounds (approximately 31.9 kg), compared to just 2.2% in the placebo group.
Eli Lilly's Chief Scientific & Medical Officer, Dan Skovronsky, stated in an interview that the 30% weight loss figure is "an incredible number," adding, "We've never seen this degree of weight loss with a drug before."
Following the announcement, Eli Lilly's stock closed up approximately 2% on Thursday. An RBC Capital Markets analyst described the trial results as a "clean win" for Eli Lilly, noting that the 28% to 30% weight loss range was precisely the success criterion previously set. A TD Cowen analyst had estimated in a January report that retatrutide could achieve sales of $3.8 billion by 2030.
**Efficacy Nears Surgical Levels, Setting New Drug Record**
A key highlight of the trial is that the weight loss in the highest dose group falls within the traditional efficacy range of bariatric surgery. Approximately 45% of patients on the highest dose achieved weight loss of 30% or more. Among patients with a BMI of 35 or higher in an extension study, the highest dose group achieved an average weight loss of 30.3% over 104 weeks. Furthermore, about 65% of patients on the highest dose had a BMI drop below 30 by week 80, moving out of the obesity category.
Kenneth Custer, President of Eli Lilly's Cardiometabolic Health division, remarked, "We are in a historic range associated with bariatric surgery, and you're achieving it with a drug." He added that the data can "definitively check the box" that retatrutide "resets the bar for maximum efficacy."
In comparison, Eli Lilly's current star weight-loss drug, Zepbound, achieves weight loss of approximately 20% to 22%, a level significantly surpassed by the highest dose of retatrutide.
**Low Dose Also Shows Promise, with Favorable Tolerability**
The trial also tested a 4 mg low-dose group for the first time, with noteworthy results. Patients in this group achieved an average weight loss of 19% (approximately 47.2 pounds) over 80 weeks, comparable to the higher doses of Zepbound but with a more favorable tolerability profile.
Dan Skovronsky pointed out that the discontinuation rate due to side effects in the 4 mg group was about 4%, lower than the nearly 5% in the placebo group—a result he called "striking." He stated, "I think we are making history, in that we can offer patients more options, both on the high end and the low end."
He also emphasized that not all patients require the highest dose, saying, "For some patients, 30% weight loss might be more than they need; for others, it might be exactly what they need to regain health."
**Side Effects and Safety: Gastrointestinal Issues Predominate, No Heart Concerns Observed**
The safety profile of retatrutide was largely consistent with other GLP-1-based drugs, with gastrointestinal side effects being the most common. In the highest dose group, approximately 42% of patients experienced nausea, about 32% had diarrhea, and around 26.1% reported constipation. Additionally, about 12% experienced dysesthesia, and about 8% had urinary tract infections. Eli Lilly noted that these latter two side effects were generally mild to moderate and resolved on their own in most cases while patients continued treatment.
The discontinuation rate due to side effects in the highest dose group was 11.3%. A BMO Capital Markets analyst noted in a research report that this dropout rate showed improvement compared to prior studies and that the strong weight loss in the low-dose group was also encouraging.
Some analysts had previously expressed concern about whether retatrutide might cause cardiac issues like arrhythmia, given that the drug targets three gut hormones including glucagon, which increases energy expenditure. Eli Lilly reported that no cardiac or liver problems were observed in the trial.
**Triple-Hormone Mechanism Builds Competitive Moat, Eli Lilly Bets on Next Core Product**
Retatrutide's differentiating advantage lies in its unique mechanism of action—it simultaneously targets three gut hormones: GLP-1, GIP, and glucagon. In contrast, Zepbound targets GLP-1 and GIP, while Novo Nordisk's Wegovy targets only GLP-1. This triple-hormone combination is believed to give retatrutide greater weight loss potential.
This marks the third set of Phase 3 results for retatrutide to date. The drug previously succeeded in a diabetes trial and passed a test last December in a study of patients with obesity and knee osteoarthritis. Recent data also showed that retatrutide helped diabetic patients achieve weight loss surpassing any existing drug and reduced pain in patients with knee osteoarthritis.
Eli Lilly positions retatrutide as the next core pillar of its obesity portfolio, following Zepbound and the newly launched oral drug Foundayo. The company hopes it will help maintain its market share advantage over Novo Nordisk. Analysts estimate the global market for weight-loss and diabetes drugs could reach approximately $100 billion by the 2030s. The success of this Phase 3 trial brings Eli Lilly a critical step closer to formally submitting the drug for regulatory approval.
Comments